Compare JOUT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOUT | LYEL |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.7M | 556.1M |
| IPO Year | 1994 | 2021 |
| Metric | JOUT | LYEL |
|---|---|---|
| Price | $51.72 | $20.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 82.7K | 65.2K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $592,415,000.00 | $36,000.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $3.70 | $8,712.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.53 | $0.40 |
| 52 Week High | $53.54 | $45.00 |
| Indicator | JOUT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 37.04 |
| Support Level | $42.87 | $15.82 |
| Resistance Level | $53.54 | $27.30 |
| Average True Range (ATR) | 2.03 | 1.43 |
| MACD | -0.15 | -0.35 |
| Stochastic Oscillator | 64.86 | 0.00 |
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.